Philadelphia Investment Partners LLC Acquires Shares of 2,526 Axsome Therapeutics, Inc. $AXSM

Philadelphia Investment Partners LLC bought a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 2,526 shares of the company’s stock, valued at approximately $619,000.

A number of other institutional investors also recently modified their holdings of the company. BlackRock Inc. acquired a new stake in Axsome Therapeutics in the 2nd quarter valued at $759,695,000. Wellington Management Group LLP raised its holdings in Axsome Therapeutics by 84.1% during the third quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock worth $162,082,000 after buying an additional 609,516 shares during the last quarter. First Trust Advisors LP lifted its stake in shares of Axsome Therapeutics by 1,230.2% in the first quarter. First Trust Advisors LP now owns 577,479 shares of the company’s stock valued at $97,606,000 after buying an additional 534,066 shares in the last quarter. Norges Bank bought a new position in shares of Axsome Therapeutics in the fourth quarter valued at $90,490,000. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Axsome Therapeutics by 45.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,509,870 shares of the company’s stock valued at $275,763,000 after buying an additional 472,422 shares during the last quarter. 81.49% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently weighed in on AXSM. TD Cowen upped their target price on shares of Axsome Therapeutics from $275.00 to $300.00 and gave the stock a “buy” rating in a report on Wednesday, June 17th. Truist Financial upgraded Axsome Therapeutics to a “strong-buy” rating in a research note on Monday, June 15th. Deutsche Bank Aktiengesellschaft set a $280.00 price objective on Axsome Therapeutics in a report on Tuesday, May 5th. Cantor Fitzgerald reissued an “overweight” rating and issued a $272.00 price objective on shares of Axsome Therapeutics in a research note on Monday, May 4th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $380.00 target price on shares of Axsome Therapeutics in a report on Thursday, June 11th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Axsome Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $267.60.

Axsome Therapeutics Stock Performance

NASDAQ AXSM opened at $207.15 on Thursday. The company has a fifty day moving average price of $229.34 and a 200-day moving average price of $206.61. The firm has a market cap of $10.85 billion, a price-to-earnings ratio of -55.24 and a beta of 0.65. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.43 and a quick ratio of 1.34. Axsome Therapeutics, Inc. has a 1 year low of $112.90 and a 1 year high of $260.19.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.10). Axsome Therapeutics had a negative net margin of 24.68% and a negative return on equity of 265.55%. The firm had revenue of $218.38 million for the quarter, compared to the consensus estimate of $221.11 million. As a group, equities research analysts predict that Axsome Therapeutics, Inc. will post -2.8 EPS for the current fiscal year.

Trending Headlines about Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating on Axsome Therapeutics, signaling continued confidence in the company’s long-term commercial outlook despite lowering its earnings forecasts.
• Neutral Sentiment: The firm continues to project a significant improvement in profitability in 2027, with positive earnings expected beginning in the second quarter and full-year 2027 EPS forecast at $5.25.
• Neutral Sentiment: A report showing zero short interest as of August 25 does not indicate meaningful short-selling pressure, although the data appears inconsistent because it also reports no change from the prior period.
• Negative Sentiment: HC Wainwright reduced its FY2026 EPS estimate to a loss of $4.10 from a loss of $3.89, while cutting forecasts for third-quarter and fourth-quarter 2026 EPS to losses of $0.95 and $0.91, respectively.
• Negative Sentiment: The analyst also lowered its 2027 estimates: first-quarter EPS was revised to a $0.27 loss from $0.05 in earnings, second-quarter EPS to $1.06 from $1.30, third-quarter EPS to $1.92 from $2.30, and full-year EPS to $5.25 from $6.47. Fourth-quarter 2027 EPS was reduced to $2.53 from $2.81.

Insider Transactions at Axsome Therapeutics

In other news, Director Roger Jeffs sold 286 shares of the business’s stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $246.18, for a total value of $70,407.48. Following the transaction, the director owned 58,653 shares in the company, valued at $14,439,195.54. The trade was a 0.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Nick Pizzie sold 33,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $240.09, for a total value of $7,922,970.00. Following the completion of the transaction, the chief financial officer directly owned 42,867 shares of the company’s stock, valued at approximately $10,291,938.03. This represents a 43.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 200,766 shares of company stock worth $46,685,646. Company insiders own 20.60% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.